Loading institutional data...
Loading institutional data...
Held by 264 of 5,944 reporting institutions (93th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $75.39 today, the market must believe free cash flow compounds 4.4%/yr for a decade (off $110M normalized FCF).
The market's 4.4% is more conservative than its 9-yr track record.
2-stage DCF · 0.02B shares · net debt $24M
mean -650.5% · volatility σ 1898% · implied rate exceeded in 3/8 yrs
Central path = implied 4.4%/yr growth; shaded band = ±1σ (1898%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| ANIP | $1.7B | 22.7× | 14.3× | 1.9× | 43.8% | — | 8.9% | 14.5% | 9.2% | 2.6× | 264 |
Peers = companies sharing ANIP's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $883.4M 100.0% | $614.4M 100.0% | $486.8M 100.0% | $316.4M 100.0% | $216.1M 100.0% | $208.5M 100.0% | $206.5M 100.0% | $201.6M 100.0% | $176.8M 100.0% | $128.6M 100.0% |
| Cost of Revenue | — | — | — | — | — | $87.2M 41.8% | $63.2M 30.6% | $73.0M 36.2% | $79.0M 44.7% | $48.8M 37.9% |
| Research & Development | $51.7M 5.8% | $44.6M 7.3% | $34.3M 7.0% | $22.3M 7.1% | $11.4M 5.3% | $16.0M 7.7% | $19.8M 9.6% | $15.4M 7.6% | $9.1M 5.1% | $2.9M 2.3% |
| Selling, General & Admin | $317.7M 36.0% | $249.6M 40.6% | $161.7M 33.2% | $124.0M 39.2% | $84.3M 39.0% | $65.0M 31.2% | $55.8M 27.0% | $44.1M 21.9% | $31.6M 17.9% | $27.8M 21.6% |
| Total Operating Expenses | $772.3M 87.4% | $613.8M 99.9% | $439.8M 90.4% | $351.7M 111.2% | $255.9M 118.4% | $224.5M 107.7% | $190.2M 92.1% | $166.2M 82.5% | $148.5M 84.0% | $108.5M 84.4% |
| Operating Income | $111.1M 12.6% | $584K 0.1% | $47.0M 9.6% | -$35.3M -11.2% | -$39.8M -18.4% | -$16.0M -7.7% | $16.4M 7.9% | $35.4M 17.5% | $28.3M 16.0% | $20.1M 15.6% |
| Interest Expense | $32.6M 3.7% | $33.6M 5.5% | $35.6M 7.3% | $28.5M 9.0% | $11.9M 5.5% | $9.5M 4.5% | $13.5M 6.5% | $14.9M 7.4% | $11.3M 6.4% | $11.3M 8.8% |
| Other Income (Expense), net | $1.9M 0.2% | -$4.0M -0.7% | -$159K -0.0% | $670K 0.2% | -$4.3M -2.0% | -$494K -0.2% | -$228K -0.1% | -$550K -0.3% | $55K 0.0% | -$74K -0.1% |
| Pretax Income | $95.8M 10.8% | -$22.2M -3.6% | $19.9M 4.1% | -$62.7M -19.8% | -$56.1M -25.9% | -$26.0M -12.5% | $3.2M 1.5% | $20.1M 9.9% | $16.3M 9.2% | $8.7M 6.7% |
| Income Tax Expense | $17.5M 2.0% | -$3.7M -0.6% | $1.1M 0.2% | -$14.8M -4.7% | -$13.5M -6.2% | -$3.4M -1.6% | -$2.9M -1.4% | $4.6M 2.3% | $17.4M 9.9% | $4.7M 3.7% |
| Net Income | $78.0M 8.8% | -$19.0M -3.1% | $19.0M 3.9% | -$48.0M -15.2% | -$43.0M -19.9% | -$22.5M -10.8% | $6.1M 3.0% | $15.5M 7.7% | -$1.1M -0.6% | $3.9M 3.1% |
| Per Share | ||||||||||
| EPS (Basic) | $3.50 | $-1.04 | $0.86 | $-3.05 | $-3.40 | $-1.88 | $0.51 | $1.31 | $-0.09 | $0.34 |
| EPS (Diluted) | $3.32 | $-1.04 | $0.85 | $-3.05 | $-3.40 | $-1.88 | $0.50 | $1.30 | $-0.09 | $0.34 |
| Weighted Avg Shares (Basic) | 20.1M | 19.3M | 18.0M | 16.3M | 12.6M | 12.0M | 11.8M | 11.7M | 11.5M | 11.4M |
| Weighted Avg Shares (Diluted) | 21.2M | 19.3M | 18.2M | 16.3M | 12.6M | 12.0M | 12.0M | 11.8M | 11.5M | 11.6M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 1% of free cash flow, leaving room to grow it and fund buybacks. Last year: $1M dividends + $12M buybacks = $13M returned on $171M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 9%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable. Effective rate ~10.5% on $309M of debt.
Cash of $286M fully covers short-term debt of $17M.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 14-yr range · 30th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 432.2× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 36.2 | 30.6 | 41.8 | — | — | — | — | — |
| R&D | 7.6 | 9.6 | 7.7 | 5.3 | 7.1 | 7.0 | 7.3 | 5.8 |
| SG&A | 21.9 | 27.0 | 31.2 | 39.0 | 39.2 | 33.2 | 40.6 | 36.0 |
| Operating Income | 17.5 | 7.9 | -7.7 | -18.4 | -11.2 | 9.6 | 0.1 | 12.6 |
| Income Tax | 2.3 | -1.4 | -1.6 | -6.2 | -4.7 | 0.2 | -0.6 | 2.0 |
| Net Income | 7.7 | 3.0 | -10.8 | -19.9 | -15.2 | 3.9 | -3.1 | 8.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ANIP: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.